Skip to main content
BEAM
NASDAQ Life Sciences

Beam Q3 Loss Widens to $134.4M; $1.0B Cash Funds Runway Into Mid-2029

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$25.31
Mkt Cap
$2.672B
52W Low
$20.23
52W High
$38.26
52W Position info
25% above low
Off High info
34% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

BEAM sits 25% above its 52-week low of $20.23.

Summary

Beam posted a $134.4M third-quarter loss ($1.28 per share) but ended September with $1.0B in cash and guided to a runway into mid-2029, covering the risto-cel BLA filing expected as early as year-end 2026.


Key Events · Earnings and Guidance · BEAM

  • Q3 Loss Widens to $134.4M

    Net loss was $134.4 million, or $1.28 per share, versus $112.6 million ($1.10) a year earlier; license and collaboration revenue fell to $0.3 million from $9.7 million.

  • Cash Covers Runway Into Mid-2029

    Cash, equivalents and marketable securities totaled $1.0 billion at September 30, 2026, down from $1.2 billion at December 31, 2025; with $200 million expected from the Sixth Street facility, runway extends into mid-2029.

  • Risto-cel BLA Targeted by Year-End

    Beam expects updated risto-cel sickle cell data and a U.S. BLA submission as early as year-end 2026, with a commercial build-out led by new chief commercial officer Eric Foster.

  • BEAM-302 Pivotal Dosing Due 1H 2027

    Enrollment and dosing continue in the global pivotal AATD cohort, with dosing completion expected in the first half of 2027; BEAM-304 PKU dosing is slated to start in early 2027.


Analysis · BEAM · Life Sciences

The balance sheet is the real story here: $1.0B in cash plus $200M expected from the Sixth Street facility funds operations into mid-2029, covering the risto-cel BLA filing expected as early as year-end 2026, BEAM-302 pivotal dosing completion in the first half of 2027, and BEAM-304 proof of concept—so no near-term financing is required. The quarter itself showed a $134.4M net loss ($1.28 per share), wider than a year ago on flat R&D and higher G&A. Revenue stays minimal ($0.3M this quarter versus $9.7M a year ago), and that widening loss is why the stock is under pressure.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BEAM was trading at $25.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $20.23 to $38.26. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BEAM - Latest Insights

BEAM
Nov 10, 2026, 7:03 AM EST
Source: Reuters
Importance Score:
9
Price at Filing: $27.40
Real-time Price: $20.97 info
Change: -$6.43 (-23%) info
Market Cap: $2.169B info
BEAM
Nov 03, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $25.87
Real-time Price: $20.97 info
Change: -$4.91 (-19%) info
Market Cap: $2.169B info
BEAM
Oct 13, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $25.47
Real-time Price: $20.97 info
Change: -$4.50 (-18%) info
Market Cap: $2.169B info
BEAM
Sep 08, 2026, 3:24 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $26.94
Real-time Price: $20.97 info
Change: -$5.97 (-22%) info
Market Cap: $2.169B info
BEAM
Sep 08, 2026, 9:22 AM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $25.95
Real-time Price: $20.97 info
Change: -$4.98 (-19%) info
Market Cap: $2.169B info